Finvest
TWST Life Sciences Tools · Synthetic biology · NGS · AI drug discovery · Thesis updated July 12, 2026

AI demand lifts Twist, but price matters

01 Running thesis

Growth is real, expectations are high

Twist's latest filing backed up the stronger story from its Q2 FY26 earnings call. Revenue grew 19% to $110.7 million. DNA synthesis and protein solutions grew 28%, while NGS applications grew 12%. That matters because the bull case now has two growth drivers: AI-enabled drug discovery demand and a recovering NGS business.

The AI story also looks less fragile than before. Management said growth that once came from a small number of accounts is now coming from dozens of accounts. That suggests customers are using Twist's platform as part of a repeat workflow, not only for one large project.

The bear case is mostly about execution and price. Management raised full-year revenue guidance to $442 million to $447 million and still expects adjusted EBITDA breakeven in Q4 FY26. If DNA synthesis slows, if NGS does not return to 20% growth by Q4 as guided, or if spending rises faster than revenue, the path to sustained profitability could slip.

May 2026▲The Q2 FY26 10-Q confirmed 19% revenue growth to $110.7 million. DNA synthesis and protein solutions grew 28%, while NGS applications grew 12%, supporting the view that both growth engines are working.
May 2026▲The Q2 earnings call strengthened the bull case. Management said AI-driven demand had broadened to dozens of accounts and guided NGS applications back to 20% growth by Q4 FY26.
Feb 2026→The Q1 FY26 10-Q confirmed the earlier earnings story and did not add material new risk factors. It supported the view that NGS was recovering while DNA synthesis stayed strong.
Feb 2026▲Q1 commentary showed repeat large orders from AI-related customers and said the prior major NGS customer issue had passed. Management also raised full-year revenue guidance by more than the Q1 beat.
Feb 2026▲The Q1 FY26 filing showed revenue growth of 16.9% to $103.7 million and gross margin of 52.0%. That supported the path toward adjusted EBITDA breakeven.
Nov 2025▲Twist introduced AI-enabled drug discovery as a bigger revenue driver and described MRD Xpress as a new cancer diagnostics product. The same update also flagged a near-term NGS slowdown from a major customer transition.
Aug 2025▲Management said gross margin above 50% was becoming a new baseline and shifted focus toward faster growth. A planned NGS customer transition created a short-term risk.
Aug 2025▲The Q3 FY25 10-Q showed revenue of $96.1 million and gross margin of 53.4%. A one-time gain from the DNA data storage sale helped produce GAAP profitability for the quarter, but the core business still needed more operating leverage.
02 Business model

A DNA factory for drug builders

Twist makes money by using its silicon-based DNA synthesis platform to produce synthetic DNA at high scale. Customers buy genes, gene fragments, oligo pools, antibody discovery work, and sequencing workflow tools. The basic idea is simple: scientists design DNA on a computer, Twist builds it, and the customer uses it in research, diagnostics, or drug discovery.

The higher-value part of the model is moving customers from basic DNA orders into full workflows. AI drug discovery companies are a key example. Many of them need a fast loop: design a molecule, build the DNA, test the protein, learn from the result, then repeat. Twist can sell into several steps of that loop.

The model breaks if speed, quality, or cost advantage fades. It also breaks if newer demand is more one-time than repeat. That is why the mix of AI revenue matters. Recurring discovery work would be much better than large model-building orders that do not repeat.

03 Product portfolio

From genes to cancer panels

Steady

Synthetic genes and gene fragments

These are core DNA building blocks for research and drug discovery. They help fill Twist's platform and bring customers into the broader product set.

Steady

Oligo pools

Oligo pools are large sets of short DNA sequences used in experiments and screening. They support the high-throughput side of Twist's platform.

Growth engine

Protein solutions and antibody discovery

This area helps drug researchers move from DNA design to protein testing and antibody optimization. It is tied closely to AI-enabled drug discovery demand.

Growth engine

NGS applications

NGS means next-generation sequencing, a way to read many DNA fragments at once. Twist sells tools such as target enrichment panels for clinical and research workflows.

Option

MRD Xpress

MRD Xpress is planned for individualized cancer monitoring panels. Management has said it can manufacture and ship tumor-informed panels in as little as 12 hours.

Option

Complex DNA offering

This is a newer product area meant to serve harder DNA designs. The key open question is how much growth it can add and when it becomes broadly available.

04 Business segments

Two engines, nearly even

DNA synthesis and protein solutions48%growing fast
NGS applications52%modest

Segment mix is from Q2 FY26, the quarter ended March 31, 2026. NGS applications were slightly larger, but DNA synthesis and protein solutions grew faster.

05 Risk factors

What could break the thesis

NGS recovery misses the target

High impact · Medium odds

Management expects NGS applications to return to 20% growth by Q4 FY26. That is a clear bar. If the segment stalls after its 12% Q2 growth and 9% sequential improvement, investors may question whether the customer transition is fully behind the company.

We watchNGS applications growth rate in Q3 and Q4 FY26, especially whether Q4 reaches the guided 20% level.

AI orders prove lumpy

High impact · Medium odds

AI-enabled drug discovery is now a major part of the bull case. Management says demand has broadened to dozens of accounts, which lowers concentration risk. The open question is whether the revenue is recurring discovery work or large one-time orders.

We watchManagement commentary on repeat orders, customer count, and the mix of recurring AI workflows versus one-time projects.

Breakeven slips again

High impact · Medium odds

Twist is still investing to support growth. Management continues to target adjusted EBITDA breakeven in Q4 FY26. If revenue falls short, those costs could push profitability farther out.

We watchQ4 FY26 adjusted EBITDA result, operating expense growth, and any change to breakeven guidance.

MRD Xpress launches slowly

Medium impact · Medium odds

MRD Xpress is an important new NGS product for cancer monitoring. The product sounds differentiated because Twist says it can ship individualized tumor-informed panels in as little as 12 hours. But the revenue and margin profile are still not clear.

We watchCommercial launch timing, early customer adoption, pricing, and gross margin commentary for MRD Xpress.

Less diversification after data storage spinout

Medium impact · Low odds

Twist spun out its DNA data storage work into Atlas Data Storage in May 2025. The filing risk is that Twist may not receive all expected benefits if Atlas does not develop or commercialize the technology well. The spinout also reduces business diversification.

We watchUpdates on Atlas Data Storage milestones and any related financial benefit or impairment risk.
06 Quick answers

In one breath

What does Twist Bioscience actually sell?

Twist sells synthetic DNA products, protein and antibody services, and tools used in next-generation sequencing. Its platform helps researchers and drug developers build and test biological designs faster.

Why is AI drug discovery important for Twist?

AI drug discovery companies need to test many designs in the lab. Twist can supply the DNA and related protein work that lets those companies run the design, build, test, learn cycle.

Is Twist Bioscience profitable?

The company is not yet built around steady GAAP profits. Management has guided for adjusted EBITDA breakeven in Q4 FY26, so the next few quarters are important.

What is the biggest thing to watch next?

Watch whether NGS applications return to 20% growth by Q4 FY26 and whether DNA synthesis keeps growing strongly. Those two signals will show whether the raised guidance was realistic.